Join to access to all OVN content. Join for Free
From Pharmacy to MSL: How an Rx background can lead to industry
pharmacy to industry transition pharmacy skills in MSL career networking for MSLs mentorship in MSL career transitioning to MSL role

From Pharmacy to MSL: How an Rx background can lead to industry


Share This Article


Summary

In this episode, Tom Caravela welcomes Cassie James to discuss her transition from pharmacy to the industry and how her pharmacy skills have been invaluable in her MSL career. Cassie shares insights from her fellowship experience and outlines essential steps for transitioning into industry roles. They explore the importance of networking, positioning, and key skills for aspiring MSLs, along with the challenges and experiences Cassie has faced in her career. The conversation highlights the significance of mentorship in the MSL career path and concludes with Cassie's final advice for aspiring MSLs.

My guest today is Kassey James, PharmD, MHA, Medical Science Liaison at Ashfield and we discuss how a Pharmacy background can lead to a role as a Medical Science Liaison

Kassey explains…

👉Why Pharmacists are good candidates for MSL positions

👉How Pharmacists can position themselves for industry roles

👉Advice on how to land a fellowship or internship

👉What skills need to be developed to transition to industry

👉What challenges exist for newer MSLs right now

Click for Source
pharmacy to industry transition, pharmacy skills in MSL career, networking for MSLs, mentorship in MSL career, transitioning to MSL role

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Types of Conferences MSLs Attend & How To Prepare...
Partner Avatar MSL Talk: Tom Caravela, George Lehman

Types of Conferences MSLs Attend & How To Prepare...

Podcast
Why Clinicians Make Great MSLs
Partner Avatar MSL Talk: Tom Caravela, Dawn O'Reilly

Why Clinicians Make Great MSLs

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
OVN Avatar Karen Geary

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Explore OVN